MedPharm to Expand its UK Analytical Service Labs
MedPharm’s £1.5-million (US$2.1-million) expansion of its Surrey, United Kingdom, facility will increase its UK laboratory space by 35% and enhance its topical and transdermal services.
MedPharm, a formulation development and analytical services company for topical and transdermal products, has invested £1.5 million (US$2.1 million) into the refurbishment and expansion of its 15,000-ft2 facility in Surrey, United Kingdom, increasing its UK laboratory space by 35%.
The expansion, which is set to be completed by the fourth quarter of 2021, will allow for a more efficient workflow and the ability for the company to continue to meet the demand for topical and transdermal services, MedPharm said in a May 20, 2021 company press release.
“We are excited to be renovating our formulation development and analytical laboratories, clinical manufacturing suites, and personnel workspace to ensure our operations and capabilities remain state of the art,” said Rob Turner, general manager UK, MedPharm, in the press release. “During the renovations, we will take extensive steps to de-risk the process and do not expect any disruption to our existing services, quality of scientific deliverables, and client commitments throughout the refurbishment.”
Source: MedPharm
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
